Most pancreatic tumors are rock hard is one of the most lethal types of cancer. Pancreatic tumors recruit a thick layer of connective tissue called stroma that hardens the tumor and acts like a shield. As a result, most chemotherapy drugs can’t build up to the levels needed to be effective, which can be achieved by this new drug for Pancreatic Cancer.
An experimental compound of a drug called PTC596 that had showed anti-tumor activity in mouse and human pancreatic cancer cells, seemed to have a durable half-life and can evade a pump that many cancer cells use to expel drugs.
PTC596 was tested in combination with gemcitabine and another drug for Pancreatic Cancer treatment, nab-paclitaxel, using human pancreatic tumors grown in mice. This combination further enhanced efficacy, making the tumors shrink outright.
PTC596 blocks the formation of microtubules–a network of proteins involved in cell division and transport of nutrients within the cell. Combining different microtubule inhibitors has the potential to play an important role in the future of oncology.